INS(Insulin)
The performance data of the INS Rapid Quantitative Test Kit(CLIA)
Manufacturer | SEKBIO |
Parameter | INS |
Linearity | 0.2-1000uIU/mL |
Detection limit | 0.01uIU/mL |
benchmark product | Roche |
Test principle and procedure | INS: Add 10 μl of sample + 30 μl of Ra, incubation for 10 minutes with cleaning, 30 μl of Rd incubation for 5 minutes. Wash with 200 μl of washing solution. Finally, add 100 μl of A + 100 μl of B. |
Six point calibration test results
Sample Concentration( uIU/ml) | RLU | Average | CV | S/N | ||
1,014.31 | 1,172,979 | 1,050,097 | 1,151,211 | 1,124,762 | 5.83% | 962.43 |
200.09 | 204,519 | 236,269 | 200,489 | 213,759 | 9.17% | 182.91 |
20.85 | 20,916 | 21,322 | 23,821 | 22,020 | 7.14% | 18.84 |
1.95 | 3,033 | 2,775 | 3,191 | 3,000 | 7.00% | 2.57 |
0.22 | 1,485 | 1,460 | 1,402 | 1,449 | 2.94% | 1.24 |
0.02 | 1,124 | 1,158 | 1,224 | 1,169 | 4.35% | 1.00 |
Precision
Sample | RLU | Concentration | Sample | RLU | Concentration |
0.25 | 3,048 | 2.00 | 15.21 | 196,412 | 184.18 |
3,002 | 1.96 | 216,766 | 202.86 | ||
3,076 | 2.03 | 221,674 | 207.36 | ||
3,191 | 2.15 | 225,286 | 210.67 | ||
3,057 | 1.98 | 206,126 | 193.10 | ||
3,053 | 2.01 | 195,386 | 183.24 | ||
3,245 | 2.21 | 190,951 | 179.16 | ||
3,269 | 2.24 | 226,027 | 211.35 | ||
3,064 | 2.02 | 226,762 | 212.02 | ||
3,409 | 2.38 | 210,788 | 197.38 | ||
AVE | 3,141 | 2.10 | AVE | 211,618 | 198.13 |
SD | 131.00 | 0.14 | SD | 13760.15 | 12.63 |
CV | 4.17% | 6.67% | CV | 6.50% | 6.37% |
Limit of detection
Sample | RLU | Concentration | ||
Ag Diluent | 1,222 | 1,206 | 0.07 | 0.06 |
1,231 | 1,267 | 0.08 | 0.09 | |
1,273 | 1,117 | 0.13 | 0.03 | |
1,270 | 1,171 | 0.09 | 0.03 | |
1,110 | 1,134 | 0.03 | 0.03 | |
1,141 | 1,331 | 0.03 | 0.19 | |
1,161 | 1,176 | 0.00 | 0.04 | |
1,223 | 1,279 | 0.07 | 0.13 | |
1,129 | 1,123 | 0.03 | 0.03 | |
1,171 | 1,262 | 0.04 | 0.14 | |
AVE | 1,200 | 0.07 | ||
SD | 65.51 | 0.05 | ||
AVE+2*SD | 0.164 | |||
Linear
Sample（uIU/ml) | Dilution ratio | Concentration value | Average | ||
1014.31 | 1.0 | 1056.80 | 948.51 | 1037.63 | 1014.31 |
811.49 | 0.8 | 767.04 | 753.74 | 760.49 | 760.42 |
608.67 | 0.6 | 552.77 | 518.70 | 582.22 | 551.23 |
405.86 | 0.4 | 342.35 | 381.00 | 354.64 | 359.33 |
203.04 | 0.2 | 224.90 | 194.47 | 199.70 | 206.36 |
0.22 | 0.0 | 0.24 | 0.22 | 0.21 | 0.22 |
Method Comparison
- Cardiac Markers
-
Tumor Marker
- CA50
-
CA125
- CA242
-
CA15-3
- CA19-9
- CA72-4
-
Pepsinogens I (PGI)
-
Human Epididymis 4 (HE4)
- Prostate-Specific Antigen (PSA)
- Squamous Cell Carcinoma (SCC)
- Neuron-Specific Enolase (NSE)
- Cytokeratin 19 Fragment (CYFRA21-1)
- Human Progastrin-releasing Peptide (ProGRP Tumor Marker)
- Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA II Tumor Marker)
- Alpha-fetoprotein(AFP)
- Inflammatory Marker
- Infectious Disease
- Hormones
- Thyroid Function
- Glucose Metabolism
- Bone Marker
- Others
-
Heterophilic Blocking Reagent
- Animal Diagnostics
